Surgical and survival outcomes with perioperative or neoadjuvant immune-checkpoint inhibitors combined with platinum-based chemotherapy in resectable NSCLC: A systematic review and meta-analysis of randomised clinical trials.

The use of neoadjuvant or perioperative anti-PD(L)1 was recently tested in multiple clinical trials. We performed a systematic review and meta-analysis of randomised trials comparing neoadjuvant or perioperative chemoimmunotherapy to neoadjuvant chemotherapy in resectable NSCLC. Nine reports from 6 studies were included. Receipt of surgery was more frequent in the experimental arm (odds ratio, OR 1.39) as was pCR (OR 7.60). EFS was improved in the experimental arm (hazard ratio, HR 0.55) regardless of stage, histology, PD-L1 expression (PD-L1 negative, HR 0.74) and smoking exposure (never smokers, HR 0.67), as was OS (HR 0.67). Grade > = 3 treatment-related adverse events were more frequent in the experimental arm (OR 1.22). The experimental treatment improved surgical outcomes, pCR rates, EFS and OS in stage II-IIIB, EGFR/ALK negative resectable NSCLC; confirmatory evidence is warranted for stage IIIB tumours and with higher maturity of the OS endpoint.

Informations de copyright

Copyright © 2023 The Authors. Published by Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: DM: none. FTG: none. SP: none. MADC: none. AT: none. RG: none. AJG: none. MR: none. MV: none. EM: none. RT: none. FLC: none. LL: none. PN: none. NP: none. MO: sub-investigator in KEYNOTE-671. MB: none. PMF: consultant for Amgen, AstraZeneca, Bristol-Myers Squibb, Daiichi Sankyo Company, F-Star, G1 Therapeutics, Genentech, Iteos, Janssen Global Services LLC, Merck, Novartis, SANOFI PASTEUR INC, Surface Oncology; grant/contract (to institution) from AstraZeneca, BioNTech, Bristol-Myers Squibb, Corvus, Kyowa Hakko Kirin, LUNGevity Foundation, Mark Foundation, NCI Cancer Center Support Grant, Novartis, Regeneron Pharmaceuticals, Stand Up To Cancer; gift (research funding) from Bloomberg Philantropies, Earl & Darielle Linehan, Martha Furman, Susan Troll. SVL: advisory board/consultant for Abbvie, Amgen, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Catalyst, Daiichi Sankyo, Eisai, Elevation Oncology, Genentech/Roche, Gilead, Guardant Health, Janssen, Jazz Pharmaceuticals, Merck, Merus, Mirati, Novartis, Regeneron, Sanofi, Takeda, Turning Point Therapeutics; research grant (to institution) from Alkermes, Elevation Oncology, Genentech, Gilead, Merck, Merus, Nuvalent, RAPT, Turning Point Therapeutics; data safety monitoring board for Candel Therapeutics. AB: none. SN: consultant for Thermo Fisher Scientific; grant/contract (to institution) from Amgen, AstraZeneca, BeiGene Switzerland GmbH, Boehringer Ingelheim, Eli Lilly and Company, F. Hoffmann-La Roche, Merck Sharp and Dohme, Novartis, PFIZER CANADA INC, SANOFI PASTEUR INC, Takeda Oncology; speaker bureau from AstraZeneca, BeiGene Switzerland GmbH, Bristol-Myers Squibb, Novartis, Takeda Oncology. GC: none. EC: none. FF: none. FC: personal fees from Roche/Genentech, AstraZeneca, Takeda, Pfizer, Bristol-Myers Squibb, Merck Sharp & Dohme, Lilly, and Bayer. DS: Advisory Board role and speaker honoraria with Astra Zeneca, MSD, BMS, Astellas, Janssenn, EISAI, Merck, Pfizer, Bayer, Novartis, Astra Zeneca, Lilly.